Pre-treatment with either the anti-IFNAR antibody, deucravacitinib (0.1 μM) or baricitinib (0.1 μM) markedly reduced Siglec-1 levels, which were close or similar to those observed in the condition with HD plasma. Here, IFNAR1 is linked to Huntington disease.